These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25690588)

  • 21. [Recommendations for management of dyslipidemia in 2014].
    Moser M; Gencer B; Rodondi N
    Rev Med Suisse; 2014 Mar; 10(420):518, 520-4. PubMed ID: 24701669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
    Ballantyne CM; Shah S; Kher U; Hunter JA; Gill GG; Cressman MD; Ashraf TB; Johnson-Levonas AO; Mitchel YB
    Am J Cardiol; 2017 Feb; 119(3):388-396. PubMed ID: 27956003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. National Lipid Association Annual Summary of Clinical Lipidology 2015.
    Bays HE; Jones PH; Brown WV; Jacobson TA;
    J Clin Lipidol; 2014; 8(6 Suppl):S1-36. PubMed ID: 25523435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East.
    Al Sayed N; Al Waili K; Alawadi F; Al-Ghamdi S; Al Mahmeed W; Al-Nouri F; Al Rukhaimi M; Al-Rasadi K; Awan Z; Farghaly M; Hassanein M; Sabbour H; Zubaid M; Barter P
    Int J Cardiol; 2016 Dec; 225():268-283. PubMed ID: 27741487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evolving Role of Non-Statin Therapy for the Management of Dyslipidemia and Cardiovascular Risk Reduction: Past, Present, and Future.
    Sisson EM; Pamulapati L; Bucheit JD; Kelly MS; Dixon DL
    Pharmacotherapy; 2018 Feb; 38(2):164-171. PubMed ID: 29266309
    [No Abstract]   [Full Text] [Related]  

  • 26. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.
    Davidson M
    Am J Cardiol; 2008 Dec; 102(12A):19L-27L. PubMed ID: 19084086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Spanish interdisciplinary committee for cardiovascular disease prevention and the spanish society of cardiology position statement on dyslipidemia management. Differences between the European and american guidelines].
    Lobos Bejarano JM; Galve E; Royo-Bordonada MÁ; Alegría Ezquerra E; Armario P; Brotons Cuixart C; Camafort Babkowski M; Cordero Fort A; Maiques Galán A; Mantilla Morató T; Pérez Pérez A; Pedro-Botet J; Villar Álvarez F; González-Juanatey JR;
    Semergen; 2015 Apr; 41(3):149-57. PubMed ID: 25450438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Managing dyslipidemia in chronic kidney disease.
    Harper CR; Jacobson TA
    J Am Coll Cardiol; 2008 Jun; 51(25):2375-84. PubMed ID: 18565393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review.
    Talasaz AH; Sadeghipour P; Aghakouchakzadeh M; Dreyfus I; Kakavand H; Ariannejad H; Gupta A; Madhavan MV; Van Tassell BW; Jimenez D; Monreal M; Vaduganathan M; Fanikos J; Dixon DL; Piazza G; Parikh SA; Bhatt DL; Lip GYH; Stone GW; Krumholz HM; Libby P; Goldhaber SZ; Bikdeli B
    J Am Coll Cardiol; 2021 Oct; 78(16):1635-1654. PubMed ID: 34649702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The new dyslipidemia guidelines: what is the debate?
    Anderson TJ; Mancini GB; Genest J; Grégoire J; Lonn EM; Hegele RA
    Can J Cardiol; 2015 May; 31(5):605-12. PubMed ID: 25816728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypertriglyceridemia and cardiovascular disease management.
    Codario RA
    J Am Acad Nurse Pract; 2007; 19(12 Suppl 2):7-10, 13-4. PubMed ID: 18510282
    [No Abstract]   [Full Text] [Related]  

  • 32. [Optimal lipid treatment: possibilities and current limitations].
    Klose G
    Internist (Berl); 2011 Mar; 52(3):328-35. PubMed ID: 21331642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients?
    Drexel H
    Fundam Clin Pharmacol; 2009 Dec; 23(6):687-92. PubMed ID: 19682084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination therapy with statins and omega-3 fatty acids.
    Nambi V; Ballantyne CM
    Am J Cardiol; 2006 Aug; 98(4A):34i-38i. PubMed ID: 16919515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia: executive summary.
    Expert Panel on Dyslipidemia
    Atherosclerosis; 2014 Feb; 232(2):410-3. PubMed ID: 24468156
    [No Abstract]   [Full Text] [Related]  

  • 36. Frontiers in Lipid Lowering Therapy: To Statins and Beyond.
    Chaudhuri A
    Eur J Vasc Endovasc Surg; 2020 Dec; 60(6):798-799. PubMed ID: 33004279
    [No Abstract]   [Full Text] [Related]  

  • 37. Combining a statin with a fibrate versus fibrate monotherapy: efficacious but safe?
    Milionis H
    Expert Opin Drug Saf; 2014 Mar; 13(3):267-9. PubMed ID: 24512564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Approach to Hypertriglyceridemia in the Pediatric Population.
    Valaiyapathi B; Sunil B; Ashraf AP
    Pediatr Rev; 2017 Sep; 38(9):424-434. PubMed ID: 28864733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Therapy of dyslipidemia in post-infarction: state of the art].
    Borgia MC; Nardi M; Da Ros S; Castellano V
    Clin Ter; 2007; 158(6):523-32. PubMed ID: 18265719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia.
    Barter P; Ginsberg HN
    Am J Cardiol; 2008 Oct; 102(8):1040-5. PubMed ID: 18929706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.